---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000008"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:22:37.706431+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics reports 2022 revenue of $699M (+30% YoY); reaffirms 2023 guidance of $940M-$1B

## Summary
- 2022 total revenue $698.8M (+30% YoY); DMD franchise $507M (+20% YoY).
- Translarna net revenue $288.6M; Emflaza $218.3M; Evrysdi royalty $113.5M.
- Net loss $559M for 2022; cash $410.7M at Dec 31, 2022.
- 2023 guidance: total revenue $940M-$1B; DMD franchise $545M-$565M.
- Four key study readouts expected H1 2023: sepiapterin PKU (May), vatiquinone MIT-E and MOVE-FA, PTC518 HD (Q2).

## SEC filing metadata
- accession: 0001070081-23-000008
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/tmb-20230221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000008
- JSON: https://secwatch.observer/filing/0001070081-23-000008.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000008.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $167.4 million. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $167.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues were $167.4 million for the fourth quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $698.8 million. Guidance reaffirmed.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $698.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenues were $698.8 million for the full year 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.